medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Number 4

<< Back Next >>

Ann Hepatol 2011; 10 (4)

Differential diagnosis of malignant epithelial tumours in the liver: an immunohistochemical study on liver biopsy material

Al-Muhannadi N, Ansari N, Brahmi U, Satir AA

Language: English
References: 18
Page: 508-515
PDF size: 196.71 Kb.


ABSTRACT

Introduction. A variety of primary and secondary malignant tumours may present in the liver. In clinical practice the most commonly encountered hepatic tumours are primary hepatocellular carcinoma, metastatic carcinoma and primary cholangiocarcinoma, each with its separate prognostic and management implications. When these tumours are poorly differentiated and the biopsy size is limited to a needle core, the distinction can be extremely difficult. Material and methods. All liver tumours reported between 1994 and 2004 were examined. Slides from each case were tested separately with each of nine antibodies (HepPar1, CD10, MOC31, Villin, pCEA, mCEA, CK7, CK19, and CK20). Results. Liver biopsy tissue from 53 patients was examined in this retrospective study. The 53 liver biopsies were classified thus: hepatocellular carcinoma (n = 23); metastatic adenocarcinoma (n = 15); cholangiocarcinoma (n = 5); metastatic small cell carcinoma (n = 7); liver cell dysplasia (n = 1); carcinoid (n = 1); and unclassified (n = 1). Sensitivity and specificity values for different antibodies in relation to their positive staining of specific tumours was as follows: HepPar1 for HCC-81.8% and 100%; MOC31 for MA-73.3% and 92.1%; MOC31 for MA and CC as a combined group-65% and 100%; pCEA (canalicular) for HCC-82.6% and 83.3%; mCEA for MA-93.3% and 75.6%; CK7 for CC-100% and 68%; CK19 for MA and CC as a combined group-90% and 86.3%. Conclusions. An antibody panel consisting of HepPar1, pCEA, CK19 and CK7 together with either MOC31 or mCEA is recommended for use in the differential diagnosis of HCC, MA and CC.


REFERENCES

  1. Fucich LF, Cheles MK, Thung SN, et al. Primary vs. metastatic hepatic carcinoma. Arch Pathol Lab Med 1994; 118: 927-30.

  2. Porcell AI, Young BRD, Proca DM, et al. Immunohistochemical analysis of hepatocellular and adenocarcinoma in the liver: MOC31 compares favorably with other putative markers. Mod Pathol 2001; 13(7): 773-8.

  3. Morrison C, Marsh W, Frankel WL. A comparison of CD 10 to pCEA, MOC-31, and hepatocyte for the distinction of malignant tumors in the liver. Mod Pathol 2002; 15(12): 1279-87.

  4. Karabork A, Kaygusuz G, Ekinci C. The best immunohistochemical panel for differentiating hepatocellular carcinoma from metastatic adenocarcinoma. Pathol Res Pract 2010; 206(8): 572-7.

  5. Wang L, Vuolo M, Suhrland MJ, Schlesinger K. HepPar1, MOC-31, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma vs. metastatic adenocarcinoma in liver fine needle aspirates. Acta Cytol 2006; 50(3): 257-62.

  6. Proca DM, Niemann TH, Porcell AI, De Young BR. MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Report of findings and review of other utilized markers. Appl Immunohistochem Mol Morphol 2000; 8(2): 120-5.

  7. Varma V, Cohen C. Immunohistochemical and molecular markers in the diagnosis of hepatocellular carcinoma. Adv Anat Pathol 2004; 11(5): 239-49.

  8. Wennerberg AE, Nalesnik MA, Coleman WB. Hepatocyte paraffin 1: A monoclonal antibody that reacts with hepatocytes and can be used for differential diagnosisof hepatic tumors. Am J Pathol 1993; 143: 1050-4.

  9. Leong AS-Y, Sormunen RT, Tsui WMS, Liew CT. Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma. Histopathology 1998; 33: 318-24.

  10. Lamps LW, Folpe AL. The diagnostic value of hepatocyte paraffin antibody 1 in differentiating hepatocellular neoplasms from non-hepatic tumors: A Review. Advanc Anat Pathol 2003; 10(1): 39-43.

  11. Fan Z, Rijn MVD, Montgomery K, et al. Hep Par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. Mod Pathol 2003; 16(2): 137-44.

  12. Lau SK, Parkash S, Geller SA, Alsabeh R. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum Pathol 2002; 33: 1175-81.

  13. Tanaka S, Hirohashi K, Uenishi T, et al. A mixed hepatocellular carcinoma and cholangiocarcinoma: Dual expression of biliary-type cytokeratin and hepatocyte specific marker. Hep Gastroenterol 2001; 51: 839-41.

  14. Borscheri N, Roessner A, Röcken C. Canalicular immunostaining of Neprilysin (CD10) as a diagnostic marker for hepatocellular carcinoma. Am J Surg Pathol 2001; 25(10): 1297-303.

  15. Saad RS, Luckasevic TM, Noga CM, et al. Diagnostic value of HepPar1, pCEA, CD10, and CD34 expression in separating hepatocellular carcinoma from metastatic carcinoma in fine needle aspiration cytology. Diagn Cytopathol 2004; 30: 1-6.

  16. Ma CK, Zarbo RJ, Frierson HF Jr, Lee MW. Comparative Immunohistochemical study of primary and metastatic carcinoma of the liver. Am J Clin Pathol 1993; 99(5): 530-2.

  17. Mcintosh GG, Lodge AJ, Watson P, et al. NCL-CD10-270: A new monoclonal antibody recognizing CD10 in Paraffin-embedded tissue. Am J Pathol 1999; 154: 77-82.

  18. Maeda T, Kajiyama K, Adachi E, et al. The expression of cytokeratin 7, 19, and 20 in primary and metastatic carcinoma of the liver. Mod Pathol 1996; 9(9): 901-9.




2020     |     www.medigraphic.com